Study Assessments/Testing | Baseline | Day | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
-2 | 0 | 7 | 14 | 21 | 28 | 35 | 42 | Next Clinic Visit | 100 | ||
Demographics (patient-, disease-, and treatment-related) | X | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Additional descriptive outcomes | Â | Â | Â | X | X | X | X | Â | Â | Â | X |
Socioeconomic status | X | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Hospital Anxiety and Depression Scale (HADS) | X | Â | X | X | X | X | X | Â | Â | Â | Â |
Blood draw for gene expression analysis | X | X | Â | Â | Â | Â | X | Â | Â | Â | Â |
Pregnancy test for females of child bearing potential | X | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Toxicity | Â | Â | X | X | X | X | X | Xa | Xa | Â | Â |
Assessment of adherenceb | Â | X | Â | Â | Â | Â | X | Â | Â | X | Â |
Heart rate and blood pressure | X | Â | X | X | X | X | X | Â | Â | X | Â |
Myeloma response assessment | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | X |